The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Abstract
Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic cells give rise to a clonal population of cells, is more common in patients exposed to cytotoxic therapies, has been shown to influence inflammatory immune programs, and is associated with an adverse prognosis in patients with NHL and MM receiving autologous transplantation. We therefore hypothesized that CHIP could influence clinical outcomes in patients receiving CAR T-cell therapy. In a cohort of 154 patients with NHL or MM receiving CAR T-cells, we found that CHIP was present in 48% of patients and associated with increased rates of complete response and cytokine release syndrome severity, but only in patients younger than age 60 years. Despite these differences, CHIP was not associated with a difference in progression-free or overall survival, regardless of age. Our data suggest that CHIP can influence CAR T-cell biology and clinical outcomes, but, in contrast to autologous transplantation, CHIP was not associated with worse survival and should not be a reason to exclude individuals from receiving this potentially life-prolonging treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which is known to promote the differentiation of IFNγ-producing CD4 + T cells and the cytolytic activity of CD8 + T cells and NK cells 177- 180 .”
From Clonal haematopoiesis and dysregulation of the immune system (2023) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Self-citationNorelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862 · cited 3×
“Moreover, DNMT3A and TET2, genes commonly mutated in CHIP, have been shown to influence CAR T-cell programs.(12,13) We therefore sought to understand the frequency and clinical consequences of CH in a cohort of patients receiving CAR T-cell therapy.”
Research works printed but not linked: 14
- Coombs, 2017, Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, Cell Stem Cell., 21, 374, 10.1016/j.stem.2017.07.010 · DOI · Paper page
- Gibson, 2017, Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J Clin Oncol., 35, 1598, 10.1200/JCO.2016.71.6712 · DOI · Paper page
- Mouhieddine, 2020, Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant, Nat Commun., 11, 2996, 10.1038/s41467-020-16805-5 · DOI
- Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
- Bick, 2020, Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis, Circulation., 141, 124, 10.1161/CIRCULATIONAHA.119.044362 · DOI · Paper page
- Miller, 2020, Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis, Blood., 136, 3051, 10.1182/blood.2020008206 · DOI
- Zebley, 2020, De novo DNA methylation programs regulate CAR T-cell exhaustion, J Immunol., 204, 246.5, 10.4049/jimmunol.204.Supp.246.5 · DOI
- Miller, 2020, Fitness landscape of clonal hematopoiesis under selective pressure of immune checkpoint blockade, JCO Precis Oncol., 4, PO.20.00186
- Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat Genet., 52, 1219, 10.1038/s41588-020-00710-0 · DOI · Paper page
- Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant., 25, 625, 10.1016/j.bbmt.2018.12.758 · DOI · Paper page
- Dong, 2014, The human SRCAP chromatin remodeling complex promotes DNA-end resection, Curr Biol., 24, 2097, 10.1016/j.cub.2014.07.081 · DOI
- Wong, 2018, Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential, Nat Commun., 9, 455, 10.1038/s41467-018-02858-0 · DOI
- Carty, 2018, The loss of TET2 promotes CD8+ T cell memory differentiation, J Immunol., 200, 82, 10.4049/jimmunol.1700559 · DOI · Paper page
- Ghoneim, 2017, De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation, Cell., 170, 142, 10.1016/j.cell.2017.06.007 · DOI · Paper page
Cited by
Clonal haematopoiesis and dysregulation of the immune system
Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161
Self-citationClonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Saini, N. Y., Swoboda, D. M., Greenbaum, U., Ma, J., Patel, R. D., Devashish, K., Das, K., Tanner, M. R., Strati, P., Nair, R., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0177 · Cited by 74
Metadata
- Authors
- Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., Neuberg, D. S., Maus, M. V., Jacobson, C., Gibson, C. J., & Ebert, B. L.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
- Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA;
- Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA;
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2021-08-03
- Volume
- 5
- Issue
- 15
- Pages
- 2982-2986
- ISSN
- 2473-9529
- 2473-9537
- Cited by
- 131
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. https://app.cochat.ai/papers/10.1182/bloodadvances.2021004554
- The paper
- Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., Neuberg, D. S., Maus, M. V., Jacobson, C., Gibson, C. J., & Ebert, B. L. (2021). Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2021004554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
